February 26, 2024 10:54 AM EST
Deals

NGM Bio to re­vert to pri­vate com­pa­ny as MASH po­ten­tial re­mains un­clear

Kyle LaHucik

Senior Reporter

Six­teen years af­ter an­nounc­ing it led NGM Bio’s $25.5 mil­lion Se­ries A, biotech in­vestor The Col­umn Group now plans to take the drug de­vel­op­ment com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: To spin off or not to spin off? Gala­pa­gos backpedals on sep­a­ra­tion plans, CEO Paul Stof­fels ex­its ear­ly

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Dutch biotech gets $146M for late-stage tri­als in three meta­bol­ic dis­or­ders

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Unit­ed­Health Group CEO An­drew Wit­ty steps down

Arc­turus to pri­or­i­tize mR­NA ther­a­peu­tics in bid to boost rare dis­ease pro­grams

A service from the Financial Times